Not all individuals with CLL involve therapy. Inspite of all current improvements, the iwCLL nevertheless endorses watchful observation for patients with asymptomatic disease.86 This suggestion is based on a minimum of two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR